Standard BioTools Q2 revenue $20.1M, down 7.6% YoY; adjusted EBITDA improves 84%

STANDARD BIOTOOLS INC.

2026-Q2 EPS reported $0.26 revenue$41,250,000

Revenue $20.1M, down 7.6% YoY; consumables $9.4M (-10%), instruments $5.1M (-2%), services $5.6M (-8%).
Net loss from continuing ops $21.5M vs $17.7M; operating loss $25.4M vs $25.7M.
Adjusted EBITDA loss $2.5M, improvement of $13.6M or 84% YoY.
Merger with Treeline Biosciences progressing; stockholder vote expected before year-end 2026.
Withdrew full year 2026 revenue outlook due to pending merger.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.